Skip to main content

Thank you for visiting nature.com. You are using a browser version with limited support for CSS. To obtain the best experience, we recommend you use a more up to date browser (or turn off compatibility mode in Internet Explorer). In the meantime, to ensure continued support, we are displaying the site without styles and JavaScript.

  • News & Views
  • Published:

TUMOR IMMUNOLOGY

PARP11 interfer(on)es with CAR T cell efficacy

Nature Cancer volume 3, pages 790–792 (2022)Cite this article

Subjects

Despite the remarkable success of chimeric antigen receptor (CAR) T cell therapies in the treatment of hematological malignancies, this strategy remains challenging in solid tumors. One major obstacle is the hostile immunosuppressive tumor microenvironment. New research demonstrates that targeting PARP11 can overcome this immunosuppression and boost CAR T cell efficacy through stabilization of IFNAR1.

This is a preview of subscription content, access via your institution

Access options

Buy this article

  • Purchase on Springer Link
  • Instant access to full article PDF
Buy now

Prices may be subject to local taxes which are calculated during checkout

Fig. 1: T cell immunosuppression induced by the adenosine–PARP11–IFNAR1 pathway.

References

  1. Mardiana, S. et al. Sci. Transl Med. 11, eaaw2293 (2019).

    Article  CAS  Google Scholar 

  2. Rafiq, S., Hackett, C. S. & Brentjens, R. J. Nat. Rev. Clin. Oncol. 17, 147–167 (2020).

    Article  Google Scholar 

  3. Rupp, L. J. et al. Sci. Rep. 7, 737 (2017).

    Article  Google Scholar 

  4. Parker, B. S., Rautela, J. & Hertzog, P. J. Nat. Rev. Cancer 16, 131–144 (2016).

    Article  Google Scholar 

  5. Katlinski, K. V. et al. Cancer Cell 31, 194–207 (2017).

    Article  CAS  Google Scholar 

  6. Zhang, H. et al. Nat. Cancer https://doi.org/10.1038/s43018-022-00383-0 (2022).

    Article  PubMed  PubMed Central  Google Scholar 

  7. Guo, T. et al. Nat. Microbiol. 4, 1872–1884 (2019).

    Article  CAS  Google Scholar 

  8. Bhattacharya, S. et al. J. Biol. Chem. 286, 22069–22076 (2011).

    Article  CAS  Google Scholar 

  9. Spiegelman, V. S. et al. Mol. Cell 5, 877–882 (2000).

    Article  CAS  Google Scholar 

  10. Stadtmauer, E. A. et al. Science 367, eaba7365 (2020).

    Article  CAS  Google Scholar 

  11. Slade, D. Genes Dev. 34, 360–394 (2020).

    Article  CAS  Google Scholar 

  12. Beavis, P. A. et al. J. Clin. Invest. 127, 929–941 (2017).

    Article  Google Scholar 

  13. Giuffrida, L. et al. Nat. Commun. 12, 3236 (2021).

    Article  CAS  Google Scholar 

  14. Kjaergaard, J. et al. J. Immunol. 201, 782–791 (2018).

    Article  CAS  Google Scholar 

  15. Bahl, K. et al. J. Immunol. 176, 4284–4295 (2006).

    Article  CAS  Google Scholar 

Download references

Acknowledgements

P.A.B. is supported by a Victorian Cancer Agency Mid-Career Fellowship (MCRF20011).

Author information

Authors and Affiliations

  1. Cancer Immunology Program, Peter MacCallum Cancer Centre, Melbourne, Victoria, Australia

    Isabelle Munoz & Paul A. Beavis

  2. Sir Peter MacCallum Department of Oncology, The University of Melbourne, Parkville, University of Melbourne, Parkville, Victoria, Australia

    Isabelle Munoz & Paul A. Beavis

Authors
  1. Isabelle Munoz
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Paul A. Beavis
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Paul A. Beavis.

Ethics declarations

Competing interests

The authors declare no competing interests.

Rights and permissions

Reprints and permissions

About this article

Check for updates. Verify currency and authenticity via CrossMark

Cite this article

Munoz, I., Beavis, P.A. PARP11 interfer(on)es with CAR T cell efficacy. Nat Cancer 3, 790–792 (2022). https://doi.org/10.1038/s43018-022-00406-w

Download citation

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1038/s43018-022-00406-w

Search

Advanced search

Quick links

Nature Briefing: Cancer

Sign up for the Nature Briefing: Cancer newsletter — what matters in cancer research, free to your inbox weekly.

Get what matters in cancer research, free to your inbox weekly. Sign up for Nature Briefing: Cancer